

Chapter 18

Psoriasis

Johann E. Gudjonsson & James T. Elder

REFERENCES

1. Raychaudhuri SP, Farber EM: The prevalence of psoriasis in the world. *J Eur Acad Dermatol Venereol* **15**(1):16-17, 2001
2. Augustin M et al: Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. *Acta Derm Venereol* **90**(2):147-151, 2010
3. Gelfand JM et al: The prevalence of psoriasis in African Americans: Results from a population-based study. *J Am Acad Dermatol* **52**(1):23-26, 2005
4. Farber EM, Nall ML: The natural history of psoriasis in 5,600 patients. *Dermatologica* **148**(1):1-18, 1974
5. Fry L: Psoriasis. *Br J Dermatol* **119**(4):445-461, 1988
6. Henseler T, Christophers E: Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris. *J Am Acad Dermatol* **13**(3):450-456, 1985
7. Nestle FO et al: Skin immune sentinels in health and disease. *Nat Rev Immunol* **9**(10):679-691, 2009
8. Steinberg A et al: A genetic and statistical study of psoriasis. *Am J Hum Gen* **3**:267-281, 1951
9. Lomholt G: Psoriasis: Prevalence, spontaneous course, and genetics. In: *Published Ph.D Thesis*, edited by G Lomholt. Copenhagen, G.E.C. GAD, 1963
10. Elder JT et al: The genetics of psoriasis. *Arch Dermatol* **130**(2):216-224, 1994
11. Andressen C, Henseler T: Inheritance of psoriasis. Analysis of 2035 family histories. *Hautarzt* **33**(4):214-217, 1982
12. Farber EM, Nall ML, Watson W: Natural history of psoriasis in 61 twin pairs. *Arch Dermatol* **109**(2):207-211, 1974
13. Brandrup F et al: Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. *Acta Derm Venereol* **62**(3):229-236, 1982
14. Duffy DL, Spelman LS, Martin NG: Psoriasis in Australian twins. *J Am Acad Dermatol* **29**(3):428-434, 1993
15. Watson W et al: The genetics of psoriasis. *Arch Dermatol* **105**(2):197-207, 1972
16. Risch N, Merikangas K: The future of genetic studies of complex human diseases. *Science* **273**(5281):1516-1517, 1996
17. Sagoo GS et al: Genome-wide studies of psoriasis susceptibility loci: A review. *J Dermatol Sci* **35**(3):171-179, 2004
18. Choonhakarn C et al: Haplotype associations of the major histocompatibility complex with psoriasis in Northeastern Thais. *Int J Dermatol* **41**(6):330-334, 2002
19. Schmitt-Egenolf M et al: Familial juvenile onset psoriasis is associated with the human leukocyte antigen (HLA) class I side of the extended haplotype Cw6-B57-DRB1*0701-DQA1*0201-DQB1*0303: A population- and family-based study. *J Invest Dermatol* **106**(4):711-714, 1996
20. Jenisch S et al: Linkage analysis of human leukocyte antigen (HLA) markers in familial psoriasis: Strong disequilibrium effects provide evidence for a major determinant in the HLA-B/-C region. *Am J Hum Genet* **63**(1):191-199, 1998
21. Gudjonsson JE et al: Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients—An analysis of 1019 HLA-C- and HLA-B-typed patients. *J Invest Dermatol* **126**(4):740-745, 2006
22. Gladman DD et al: HLA-C locus alleles in patients with psoriatic arthritis (PsA). *Hum Immunol* **60**(3):259-261, 1999
23. Espinoza LR et al: Histocompatibility typing in the seronegative spondyloarthropathies: A survey. *Semin Arthritis Rheum* **11**(3):375-381, 1982
24. Ozawa A et al: HLA class I and II alleles and susceptibility to generalized pustular psoriasis: Significant associations with HLA-Cw1 and HLA-DQB1*0303. *J Dermatol* **25**(9):573-581, 1998
25. Stuart PE et al: Comparison of MHC class I risk haplotypes in Thai and Caucasian psoriatics reveals locus heterogeneity at PSORS1. *Tissue Antigens* **76**(5):387-397, 2010
26. Mallon E et al: HLA-C and guttate psoriasis. *Br J Dermatol* **143**(6):1177-1182, 2000

27. Barber LD et al: The inter-locus recombinant HLA-B*4601 has high selectivity in peptide binding and functions characteristic of HLA-C. *J Exp Med* **184**(2):735-740, 1996
28. Walsh EC et al: An integrated haplotype map of the human major histocompatibility complex. *Am J Hum Genet* **73**(3):580-590, 2003
29. Horton R et al: Gene map of the extended human MHC. *Nat Rev Genet* **5**(12):889-899, 2004
30. Nair RP et al: Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. *Am J Hum Genet* **78**(5):827-851, 2006
31. Allen M et al: Corneodesmosin expression in psoriasis vulgaris differs from normal skin and other inflammatory skin disorders. *Lab Invest* **81**(7):969-976, 2001
32. Fan X et al: Fine mapping of the psoriasis susceptibility locus PSORS1 supports HLA-C as the susceptibility gene in the Han Chinese population. *PLoS Genet* **4**(3):e1000038, 2008
33. Feng BJ et al: Multiple loci within the major histocompatibility complex confer risk of psoriasis. *PLoS Genet* **5**(8):e1000606, 2009
34. Nair RP et al: Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. *Nat Genet* **41**(2):199-204, 2009
35. Trembath RC et al: Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. *Hum Mol Genet* **6**(5):813-820, 1997
36. Karason A et al: Genetics of psoriasis in Iceland: Evidence for linkage of subphenotypes to distinct Loci. *J Invest Dermatol* **124**(6):1177-1185, 2005
37. Tomfohrde J et al: Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. *Science* **264**(5162):1141-1145, 1994
38. Nair RP et al: Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. *Hum Mol Genet* **6**(8):1349-1356, 1997
39. Samuelsson L et al: A genome-wide search for genes predisposing to familial psoriasis by using a stratification approach. *Hum Genet* **105**(6):523-529, 1999
40. Hwu WL et al: Mapping of psoriasis to 17q terminus. *J Med Genet* **42**(2):152-158, 2005
41. Zheng J, Jin S, Shi R: Confirmation of PSORS psoriasis susceptibility loci in a Chinese population. *Arch Dermatol Res* **295**(1):14-18, 2003
42. Bhalerao J, Bowcock AM: The genetics of psoriasis: A complex disorder of the skin and immune system. *Hum Mol Genet* **7**(10):1537-1545, 1998
43. Capon F et al: Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. *J Invest Dermatol* **116**(5):728-730, 2001
44. Enlund F et al: Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden. *Eur J Hum Genet* **7**(7):783-790, 1999
45. Hewett D et al: Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. *Genomics* **79**(3):305-314, 2002
46. Huffmeier U et al: Systematic linkage disequilibrium analysis of SLC12A8 at PSORS5 confirms a role in susceptibility to psoriasis vulgaris. *J Invest Dermatol* **125**(5):906-912, 2005
47. Karason A et al: A susceptibility gene for psoriatic arthritis maps to chromosome 16q: Evidence for imprinting. *Am J Hum Genet* **72**(1):125-131, 2003
48. Zhang XJ et al: Evidence for a major psoriasis susceptibility locus at 6p21(PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese hans. *J Invest Dermatol* **119**(6):1361-1366, 2002
49. Sagoo GS et al: Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans population. *J Invest Dermatol* **122**(6):1401-1405, 2004
50. Bowcock AM, Krueger JG: Getting under the skin: The immunogenetics of psoriasis. *Nat Rev Immunol* **5**(9):699-711, 2005
51. Hüffmeier U et al: Lack of evidence for genetic association to RUNX1 binding site at PSORS2 in different German psoriasis cohorts. *J Invest Dermatol* **124**(1):107-110, 2005
52. Stuart P et al: Analysis of RUNX1 binding site and RAPTOR polymorphisms in psoriasis: No evidence for association despite adequate power and evidence for linkage. *J Med Genet* **43**(1):12-17, 2006
53. Segre JA: Epidermal barrier formation and recovery in skin disorders. *J Clin Invest* **116**(5):1150-1158, 2006
54. Altshuler D et al: A haplotype map of the human genome. *Nature* **437**(7063):1299-1320, 2005
55. Li Y et al: Genotype imputation. *Annu Rev Genomics Hum Genet* **10**:387-406, 2009

56. Elder JT et al: Molecular dissection of psoriasis: Integrating genetics and biology. *J Invest Dermatol* **130**(5):1213-1226, 2010
57. Zhang XJ et al: Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. *Nat Genet* **41**(2):205-210, 2009
58. Ellinghaus E et al: Genome-wide association study reveals association of psoriasis with TRAF3IP2. *Nat Genet* **42**(11):991-995, 2010
59. Stuart LD et al: Follow-up study identifies six novel psoriasis susceptibility loci in the Chinese Han population. *Nat Genet* **42**(11):1005-1009, 2010
60. Cargill M et al: A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. *Am J Hum Genet* **80**(2):273-290, 2007
61. Strange A et al: A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. *Nat Genet* **42**(11):985-990, 2010
62. Capon F et al: Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. *Hum Mol Genet* **17**(13):1938-1945, 2008
63. Chang M et al: Variants in the 5q31 cytokine gene cluster are associated with psoriasis. *Genes Immun* **9**(2):176-181, 2008
64. Stuart PE et al: Identification of novel susceptibility loci for psoriasis and psoriatic arthritis. *Nat Genet* **42**(11):1000-1004, 2010
65. de Cid R et al: Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. *Nat Genet* **41**(2):211-215, 2009
66. Hollox EJ et al: Psoriasis is associated with increased beta-defensin genomic copy number. *Nat Genet* **40**(1):23-25, 2008
67. Braun-Falco O: Dynamics of growth and regression in psoriatic lesions: Alterations in the skin from normal into a psoriatic lesion, and during regression of psoriatic lesions. In: *Psoriasis: Proceedings of the International Symposium, Stanford University, 1971*, edited by EM Farber, AJ Cox. Stanford, CA, Stanford University Press, 1971, pp. 215-237
68. Wilkinson DI: Lipid metabolism in psoriasis. In: *Psoriasis: Proceedings of the International Symposium, Stanford University, 1971*, edited by EM Farber, AJ Cox. Stanford, CA, Stanford University Press, 1971, pp. 277-285
69. Gudjonsson JE et al: Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. *J Invest Dermatol* **129**(12):2795-2804, 2009
70. Christophers E, Parzefall R, Braun-Falco O: Initial events in psoriasis: Quantitative assessment. *Br J Dermatol* **89**(4):327-334, 1973
71. Ragaz A, Ackerman AB: Evolution, maturation, and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings. *Am J Dermatopathol* **1**(3):199-214, 1979
72. Brody I: Alterations of clinically normal skin in early eruptive guttate psoriasis. *J Cutan Pathol* **5**:219-233, 1978
73. Brody I: Mast cell degranulation in the evolution of acute eruptive guttate psoriasis vulgaris. *J Invest Dermatol* **82**(5):460-464, 1984
74. Schubert C, Christophers E: Mast cells and macrophages in early relapsing psoriasis. *Arch Dermatol Res* **277**(5):352-358, 1985
75. Baker BS et al: Epidermal T lymphocytes and HLA-DR expression in psoriasis. *Br J Dermatol* **110**(5):555-564, 1984
76. Bieber T, Braun-Falco O: Distribution of CD1a-positive cells in psoriatic skin during the evolution of the lesions. *Acta Derm Venereol* **69**(2):175-178, 1989
77. Wright NA, Camplejohn RS, eds.: *Psoriasis: Cell Proliferation*. Edinburgh, London, Melbourne, and New York, Churchill Livingstone, 1983
78. Cox AJ, Watson W: Histological variations in lesions of psoriasis. *Arch Dermatol* **106**(4):503-506, 1972
79. Nestle FO, Kaplan DH, Barker J: Psoriasis. *N Engl J Med* **361**(5):496-509, 2009
80. Gaspari AA: Innate and adaptive immunity and the pathophysiology of psoriasis. *J Am Acad Dermatol* **54**(3 Suppl. 2):S67-S80, 2006
81. Baker BS et al: Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: The effects of PUVA treatment. *Clin Exp Immunol* **61**(3):526-534, 1985
82. Ellis CN et al: Cyclosporine improves psoriasis in a double-blind study. *JAMA* **256**(22):3110-3116, 1986
83. Griffiths C et al: Clearance of psoriasis with low dose cyclosporin. *Br Med J* **293**:731-732, 1986
84. Elder JT et al: Cyclosporin A rapidly inhibits epidermal cytokine expression in psoriasis lesions, but not in cytokine-stimulated cultured keratinocytes. *J Invest Dermatol* **101**:761-766, 1993

85. Kanamori H et al: Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: Case report and review of the literature. *Am J Hematol* **71**(1):41-44, 2002
86. Gardembas-Pain M et al: Psoriasis after allogeneic bone marrow transplantation [letter]. *Arch Dermatol* **126**(11):1523, 1990
87. Wrone-Smith T, Nickoloff BJ: Dermal injection of immunocytes induces psoriasis. *J Clin Invest* **98**(8):1878-1887, 1996
88. Chang JC et al: CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes. *Proc Natl Acad Sci U S A* **91**(20):9282-9286, 1994
89. Prinz JC et al: Selection of conserved TCR VDJ rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris. *Eur J Immunol* **29**(10):3360-3368, 1999
90. Vollmer S, Menssen A, Prinz JC: Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: Evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris. *J Invest Dermatol* **117**(5):1296-1301, 2001
91. Lin WJ et al: Oligoclonal expansion of intraepidermal T cells in psoriasis skin lesions. *J Invest Dermatol* **117**(6):1546-1553, 2001
92. Clark RA et al: The vast majority of CLA+ T cells are resident in normal skin. *J Immunol* **176**(7):4431-4439, 2006
93. Austin LM et al: Intraepidermal lymphocytes in psoriatic lesions are activated GMP-17(TIA-1)+CD8+CD3+ CTLs as determined by phenotypic analysis. *J Cutan Pathol* **25**(2):79-88, 1998
94. Paukkonen K, Naukkarinen A, Horsmanheimo M: The development of manifest psoriatic lesions is linked with the invasion of CD8+ T cells and CD11c+macrophages into the epidermis. *Arch Dermatol Res* **284**(7):375-379, 1992
95. Uyemura K et al: The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. *J Invest Dermatol* **101**(5):701-705, 1993
96. Austin LM et al: The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. *J Invest Dermatol* **113**(5):752-759, 1999
97. Zaba LC et al: Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. *J Exp Med* **204**(13):3183-3194, 2007
98. Eyerich S et al: Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. *J Clin Invest* **119**(12):3573-3585, 2009
99. Iwakura Y, Ishigame H: The IL-23/IL-17 axis in inflammation. *J Clin Invest* **116**(5):1218-1222, 2006
100. Murphy CA et al: Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. *J Exp Med* **198**(12):1951-1957, 2003
101. Piskin G et al: In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin. *J Immunol* **176**(3):1908-1915, 2006
102. Yen HR et al: Tc17 CD8 T cells: Functional plasticity and subset diversity. *J Immunol* **183**(11):7161-7168, 2009
103. Annunziato F et al: Phenotypic and functional features of human Th17 cells. *J Exp Med* **204**(8):1849-1861, 2007
104. Bending D et al: Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. *J Clin Invest* **119**(3):565-572, 2009
105. Wei G et al: Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. *Immunity* **30**(1):155-167, 2009
106. Zheng Y et al: Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. *Nature* **445**(7128):648-651, 2007
107. Nogral KE et al: IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing T(H)17 T cells. *J Allergy Clin Immunol* **123**(6):1244-1252, 2009
108. Trifari S et al: Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. *Nat Immunol* **10**(8):864-871, 2009
109. Manel N, Unutmaz D, Littman DR: The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgamma. *Nat Immunol* **9**(6):641-649, 2008
110. Wing K, Sakaguchi S: Regulatory T cells exert checks and balances on self tolerance and autoimmunity. *Nat Immunol* **11**(1):7-13, 2010

111. Beissert S, Schwarz A, Schwarz T: Regulatory T cells. *J Invest Dermatol* **126**(1):15-24, 2006
112. Sugiyama H et al: Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: Mechanism underlying unrestrained pathogenic effector T cell proliferation. *J Immunol* **174**(1):164-173, 2005
113. Goodman WA et al: IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. *J Immunol* **183**(5):3170-3176, 2009
114. Peternel S, Kastelan M: Immunopathogenesis of psoriasis: Focus on natural killer T cells. *J Eur Acad Dermatol Venereol* **23**(10):1123-1127, 2009
115. Ferenczi K et al: CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: Blood and skin comparisons by flow cytometry. *J Autoimmun* **14**(1):63-78, 2000
116. Bonish B et al: Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. *J Immunol* **165**(7):4076-4085, 2000
117. Nickoloff BJ et al: Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. *J Dermatol Sci* **24**(3):212-225, 2000
118. Rajagopalan S, Long EO: Understanding how combinations of HLA and KIR genes influence disease. *J Exp Med* **201**(7):1025-1029, 2005
119. Suzuki Y et al: Genetic polymorphisms of killer cell immunoglobulin-like receptors are associated with susceptibility to psoriasis vulgaris. *J Invest Dermatol* **122**(5):1133-1136, 2004
120. Holm SJ et al: Distinct HLA-C/KIR genotype profile associates with guttate psoriasis. *J Invest Dermatol* **125**(4):721-730, 2005
121. Ploski R et al: A role for KIR gene variants other than KIR2DS1 in conferring susceptibility to psoriasis. *Hum Immunol* **67**(7):521-526, 2006
122. Martin MP et al: Cutting edge: Susceptibility to psoriatic arthritis: Influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. *J Immunol* **169**(6):2818-2822, 2002
123. Williams F et al: Activating killer cell immunoglobulin-like receptor gene KIR2DS1 is associated with psoriatic arthritis. *Hum Immunol* **66**(7):836-841, 2005
124. Nelson GW et al: Cutting edge: Heterozygote advantage in autoimmune disease: Hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. *J Immunol* **173**(7):4273-4276, 2004
125. Reis e Sousa C: Dendritic cells in a mature age. *Nat Rev Immunol* **6**(6):476-483, 2006
126. Wollenberg A et al: Plasmacytoid dendritic cells: A new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. *J Invest Dermatol* **119**(5):1096-1102, 2002
127. Krueger JG, Bowcock A: Psoriasis pathophysiology: Current concepts of pathogenesis. *Ann Rheum Dis* **64**(Suppl. 2):ii30-ii36, 2005
128. Zaba LC, Krueger JG, Lowes MA: Resident and "inflammatory" dendritic cells in human skin. *J Invest Dermatol* **129**(2):302-308, 2009
129. Kripke ML et al: Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization. *J Immunol* **145**(9):2833-2838, 1990
130. Wollenberg A et al: Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. *J Invest Dermatol* **106**(3):446-453, 1996
131. Abrams JR et al: Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4lg) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. *J Exp Med* **192**(5):681-694, 2000
132. Fujita H et al: Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. *Proc Natl Acad Sci U S A* **106**(51):21795-21800, 2009
133. Cumberbatch M et al: Impaired Langerhans cell migration in psoriasis. *J Exp Med* **203**(4):953-960, 2006
134. Shaw FL et al: Langerhans cell mobilization distinguishes between early-onset and late-onset psoriasis. *J Invest Dermatol* **130**(7):1940-1942, 2010
135. Nestle FO et al: Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. *J Immunol* **151**(11):6535-6545, 1993
136. Morganroth GS et al: Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells. *J Invest Dermatol* **96**(3):333-340, 1991

137. Lowes MA et al: Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). *Proc Natl Acad Sci U S A* **102**(52):19057-19062, 2005
138. Cerio R et al: Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. *Br J Dermatol* **121**(4):421-431, 1989
139. Zaba LC et al: Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIa+ macrophages. *J Clin Invest* **117**(9):2517-2525, 2007
140. Zaba LC et al: Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. *J Allergy Clin Immunol* **125**(6):1261-1268, e1269, 2010
141. Lew W, Bowcock AM, Krueger JG. Psoriasis vulgaris: Cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. *Trends Immunol* **25**(6):295-305, 2004
142. Zaba LC et al: Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. *J Invest Dermatol* **129**(1):79-88, 2009
143. Guttman-Yassky E et al: Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. *J Allergy Clin Immunol* **119**(5):1210-1217, 2007
144. Wollenberg A et al: Expression and function of the mannose receptor CD206 on epidermal dendritic cells in inflammatory skin diseases. *J Invest Dermatol* **118**(2):327-334, 2002
145. Johnson-Huang LM et al: Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. *J Clin Immunol* **29**(3):247-256, 2009
146. Colonna M, Trinchieri G, Liu YJ: Plasmacytoid dendritic cells in immunity. *Nat Immunol* **5**(12):1219-1226, 2004
147. Nestle FO et al: Plasmacytoid predendritic cells initiate psoriasis through interferon- α production. *J Exp Med* **202**(1):135-143, 2005
148. Rajan N, Langtry JA: Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. *Clin Exp Dermatol* **31**(1):140-141, 2006
149. Hemmi H et al: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. *Nat Immunol* **3**(2):196-200, 2002
150. Bissonnette R et al: A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon- α monoclonal antibody, in subjects with chronic psoriasis. *J Am Acad Dermatol* **62**(3):427-436, 2010
151. Marone G et al: Pharmacological modulation of human mast cells and basophils. *Clin Exp Allergy* **32**(12):1682-1689, 2002
152. Hueber AJ et al: Mast cells express IL-17A in rheumatoid arthritis synovium. *J Immunol* **184**(7):3336-3340, 2010
153. Lin A et al: Mast cells and neutrophils are major sources of IL-17 in psoriasis. *J Immunol* **187**(1):490-500, 2011
154. Fuentes-Duculan J et al: A subpopulation of CD163-positive macrophages is classically activated in psoriasis. *J Invest Dermatol* **130**(10):2412-2422, 2010
155. Gillitzer R et al: MCP-1 mRNA expression in basal keratinocytes of psoriatic lesions. *J Invest Dermatol* **101**(2):127-131, 1993
156. Van Den Oord JJ, de Wolf-Peeters C: Epithelium-lining macrophages in psoriasis. *Br J Dermatol* **130**(5):589-594, 1994
157. Boehncke WH et al: A subset of macrophages located along the basement membrane ("lining cells") is a characteristic histopathological feature of psoriasis. *Am J Dermatopathol* **17**(2):139-144, 1995
158. Pinkus H, Nehregan AH: The primary histologic lesion of seborrheic dermatitis and psoriasis. *J Invest Dermatol* **46**:109-116, 1966
159. Clark RA, Kupper TS: Misbehaving macrophages in the pathogenesis of psoriasis. *J Clin Invest* **116**(8):2084-2087, 2006
160. Wang H et al: Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasisiform skin inflammation. *J Clin Invest* **116**(8):2105-2114, 2006
161. Stratis A et al: Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. *J Clin Invest* **116**(8):2094-2104, 2006
162. Grone A: Keratinocytes and cytokines. *Vet Immunol Immunopathol* **88**(1-2):1-12, 2002
163. Duell EA, Ellis CN, Voorhees JJ: Determination of 5,12, and 15-lipoxygenase products in keratomed biopsies of normal and psoriatic skin. *J Invest Dermatol* **91**(5):446-450, 1988
164. Braff MH et al: Cutaneous defense mechanisms by antimicrobial peptides. *J Invest Dermatol* **125**(1):9-13, 2005

165. Mansbridge JN, Knapp AM, Strefling AM: Evidence for an alternative pathway of keratinocyte maturation in psoriasis from an antigen found in psoriatic but not normal epidermis. *J Invest Dermatol* **83**(4):296-301, 1984
166. Krueger JG et al: Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. *J Exp Med* **182**(6):2057-2068, 1995
167. Detmar M et al: Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. *J Exp Med* **180**:1141-1146, 1994
168. Xia YP et al: Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. *Blood* **102**(1):161-168, 2003
169. Creamer D et al: Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. *Br J Dermatol* **136**(6):859-865, 1997
170. Szabowski A et al: c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. *Cell* **103**(5):745-755, 2000
171. Saiag P et al: Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro. *Science* **230**(4726):669-672, 1985
172. Clark RA et al: A novel method for the isolation of skin resident T cells from normal and diseased human skin. *J Invest Dermatol* **126**(5):1059-1070, 2006
173. Prinz JC et al: T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. *Eur J Immunol* **24**(3):593-598, 1994
174. Bata-Csorgo Z et al: Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninjured, but not normal, stem keratinocytes. *J Clin Invest* **95**(1):317-327, 1995
175. Nickoloff BJ et al: Decreased growth inhibition by recombinant gamma interferon is associated with increased transforming growth factor-alpha production in keratinocytes cultured from psoriatic lesions. *Br J Dermatol* **121**(2):161-174, 1989
176. Uyemura K et al: CD4+ type 1 and CD8+ type 2 T cell subsets in human leishmaniasis have distinct T cell receptor repertoires. *J Immunol* **151**(12):7095-7104, 1993
177. Ettehadi P et al: Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. *Clin Exp Immunol* **96**(1):146-151, 1994
178. Grossman RM et al: Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. *Proc Natl Acad Sci U S A* **86**(16):6367-6371, 1989
179. Degiulio R et al: Increased levels of leukotriene B4 and interleukin-8 in psoriatic skin. *Ann N Y Acad Sci* **685**:614-617, 1993
180. Ruckert R et al: High-dose proinflammatory cytokines induce apoptosis of hair bulb keratinocytes in vivo [In Process Citation]. *Br J Dermatol* **143**(5):1036-1039, 2000
181. Teunissen MB et al: Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. *J Invest Dermatol* **111**(4):645-649, 1998
182. Ohta Y, Hamada Y, Katsuoka K: Expression of IL-18 in psoriasis. *Arch Dermatol Res* **293**(7):334-342, 2001
183. Sa SM et al: The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. *J Immunol* **178**(4):2229-2240, 2007
184. Caruso R et al: Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. *Nat Med* **15**(9):1013-1015, 2009
185. Nickoloff BJ et al: The cytokine and chemokine network in psoriasis. *Clin Dermatol* **25**(6):568-573, 2007
186. Li AG et al: Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. *Embo J* **23**(8):1770-1781, 2004
187. Mee JB et al: Interleukin-1: A key inflammatory mediator in psoriasis? *Cytokine* **33**(2):72-78, 2006
188. Gudjonsson JE, Elder JT: Psoriasis: Etiopathogenesis. In: *Psoriatic and Reactive Arthritis: A Companion to Rheumatology*, 1st edition, edited by C Riechlin, CT Riechlin, O Fitzgerald. Philadelphia, Elsevier, 2006, pp. 37-47
189. Harrington LE et al: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. *Nat Immunol* **6**(11):1123-1132, 2005
190. Kryczek I et al: Induction of memory IL-17+ T cell trafficking and expansion by IFN-gamma: Mechanism and pathological relevance. *J Immunol* **181**:4733-4741, 2008

191. Conrad C et al: Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. *Nat Med* **13**(7):836-842, 2007
192. Ong PY et al: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. *N Engl J Med* **347**(15):1151-1160, 2002
193. de Jongh GJ et al: High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. *J Invest Dermatol* **125**(6):1163-1173, 2005
194. Howell MD et al: Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. *J Invest Dermatol* **125**(4):738-745, 2005
195. Christophers E, Henseler T: Contrasting disease patterns in psoriasis and atopic dermatitis. *Arch Dermatol Res* **279**(Suppl.):S48-S51, 1987
196. Eckert RL et al: S100 proteins in the epidermis. *J Invest Dermatol* **123**(1):23-33, 2004
197. Clohessy PA, Golden BE: Calprotectin-mediated zinc chelation as a biostatic mechanism in host defence. *Scand J Immunol* **42**(5):551-556, 1995
198. Glaser R et al: Antimicrobial psoriasin (S100A7) protects human skin from *Escherichia coli* infection. *Nat Immunol* **6**(1):57-64, 2005
199. Loser K et al: The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8(+) T cells. *Nat Med* **16**(6):713-717, 2010
200. Takematsu H, Tagami J: Quantification of chemotactic peptides (C5a anaphylatoxin and IL-8) in psoriatic lesional skin. *Arch Dermatol* **129**:74-80, 1993
201. Mrowietz U et al: Psoriasis scales contain C5a as the predominant chemotaxin for monocyte-derived dendritic cells. *Exp Dermatol* **10**(4):238-245, 2001
202. McInturff JE, Modlin RL, Kim J: The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. *J Invest Dermatol* **125**(1):1-8, 2005
203. Ikai K: Psoriasis and the arachidonic acid cascade. *J Dermatol Sci* **21**(3):135-146, 1999
204. Elder J: Cytokine and genetic regulation of psoriasis. In: *Advances in Dermatology*, vol. 10, edited by M Dahl. St. Louis, Mosby-Year Book, 1995, pp. 99-134
205. Piepkorn M, Pittelkow MR, Cook PW: Autocrine regulation of keratinocytes: The emerging role of heparin-binding, epidermal growth factor-related growth factors. *J Invest Dermatol* **111**(5):715-721, 1998
206. Bhagavathula N et al: Amphiregulin and epidermal hyperplasia: Amphiregulin is required to maintain the psoriatic phenotype of human skin grafts on severe combined immunodeficient mice. *Am J Pathol* **166**(4):1009-1016, 2005
207. Malhotra R et al: Angiogenic properties of normal and psoriatic skin associate with epidermis, not dermis. *Lab Invest* **61**(2):162-165, 1989
208. Joseph T et al: Unilateral remission of psoriasis following traumatic nerve palsy. *Br J Dermatol* **152**(1):185-186, 2005
209. Raychaudhuri SP et al: K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model. *J Invest Dermatol* **122**(3):812-819, 2004
210. Hosoi J et al: Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. *Nature* **363**(6425):159-163, 1993
211. Krane JF et al: The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor. *J Exp Med* **175**(4):1081-1090, 1992
212. Finch PW et al: Altered expression of keratinocyte growth factor and its receptor in psoriasis. *Am J Pathol* **151**(6):1619-1628, 1997
213. Sanderson MP, Dempsey PJ, Dunbar AJ: Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. *Growth Factors* **24**(2):121-136, 2006
214. Meyer-Hoffert U, Wingerts Zahn J, Wiedow O: Human leukocyte elastase induces keratinocyte proliferation by epidermal growth factor receptor activation. *J Invest Dermatol* **123**(2):338-345, 2004
215. Iwakiri K, Ghazizadeh M, Jin E et al: Human airway trypsin-like protease induces PAR-2-mediated IL-8 release in psoriasis vulgaris. *J Invest Dermatol* **122**(4):937-944, 2004
216. Pfundt R et al: Constitutive and inducible expression of SKALP/elafin provides anti-elastase defense in human epithelia. *J Clin Invest* **98**(6):1389-1399, 1996
217. Bylaite M et al: Expression of cathepsin L and its inhibitor hurpin in inflammatory and neoplastic skin diseases. *Exp Dermatol* **15**(2):110-118, 2006
218. Fyrand O: Studies on fibronectin in the skin. II. Indirect immunofluorescence studies in psoriasis vulgaris. *Arch Dermatol Res* **266**(1):33-41, 1979
219. Bata-Csorgo Z et al: Fibronectin and alpha5 integrin regulate keratinocyte cell cycling. A mechanism for increased fibronectin potentiation of T

- cell lymphokine-driven keratinocyte hyperproliferation in psoriasis. *J Clin Invest* **101**(7):1509-1518, 1998
220. De Luca M et al: Role of integrins in cell adhesion and polarity in normal keratinocytes and human skin pathologies. *J Dermatol* **21**(11):821-828, 1994
221. Carroll JM, Romero MR, Watt FM: Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. *Cell* **83**(6):957-968, 1995
222. Rottman JB et al: Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alpha-Ebeta7 in the pathogenesis of psoriasis vulgaris. *Lab Invest* **81**(3):335-347, 2001
223. Gudjonsson JE et al: Evidence for altered Wnt signaling in psoriatic skin. *J Invest Dermatol* **130**(7):1849-1859, 2010
224. Nickoloff BJ, Nestle FO: Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. *J Clin Invest* **113**(12):1664-1675, 2004
225. Raj D, Brash DE, Grossman D: Keratinocyte apoptosis in epidermal development and disease. *J Invest Dermatol* **126**(2):243-257, 2006
226. Gudjonsson JE et al: Mouse models of psoriasis. *J Invest Dermatol* **127**(6):1292-1308, 2007
227. Gudjonsson JE et al: Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. *Br J Dermatol* **149**(3):530-534, 2003
228. Akagi Y et al: A role of tonsillar lymphocyte for focal infection. With special reference to lymphocyte adhesion to vessels in dermis. *Adv Otorhinolaryngol* **47**:129-133, 1992
229. Diluvio L et al: Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. *J Immunol* **176**(11):7104-7111, 2006
230. Gudjonsson JE et al: Immunopathogenic mechanisms in psoriasis. *Clin Exp Immunol* **135**(1):1-8, 2004
231. Hammar H et al: Subpopulations of mononuclear cells in microscopic lesions of psoriatic patients. Selective accumulation of suppressor/cytotoxic T cells in epidermis during the evolution of the lesion. *J Invest Dermatol* **83**(6):416-420, 1984
232. Boyman O et al: Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. *J Exp Med* **199**(5):731-736, 2004
233. Clark RA: Skin-resident T cells: The ups and downs of on site immunity. *J Invest Dermatol* **130**(2):362-370, 2010
234. Martin BA, Chalmers RJ, Telfer NR: How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? *Arch Dermatol* **132**(6):717-718, 1996
235. Valdimarsson H et al: Psoriasis—As an autoimmune disease caused by molecular mimicry. *Trends Immunol* **30**(10):494-501, 2009
236. Braun-Falco O, Schmoeckel C: The dermal inflammatory reaction in initial psoriatic lesions. *Arch Dermatol Res* **258**(1):9-16, 1977
237. Fischetti VA: Streptococcal M protein. *Sci Am* **264**(6):58-65, 1991
238. Sigmundsdottir H et al: Circulating T cells of patients with active psoriasis respond to streptococcal M-peptides sharing sequences with human epidermal keratins. *Scand J Immunol* **45**(6):688-697, 1997
239. Gudmundsdottir AS et al: Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis? *Clin Exp Immunol* **117**(3):580-586, 1999
240. McFadden J, Valdimarsson H, Fry L. Cross-reactivity between streptococcal M surface antigen and human skin. *Br J Dermatol* **125**(5):443-447, 1991
241. Leigh IM et al: Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. *Br J Dermatol* **133**(4):501-511, 1995
242. Johnston A et al: Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells. *Clin Exp Immunol* **138**(1):83-93, 2004
243. Kurts C et al: Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. *J Exp Med* **188**(2):409-414, 1998
244. Stoler A et al: Use of monospecific antisera and cRNA probes to localize the major changes in keratin expression during normal and abnormal epidermal differentiation. *J Cell Biol* **107**(2):427-446, 1988
245. Zhou X et al: Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. *Physiol Genomics* **13**(1):69-78, 2003

246. Gudjonsson JE, Ding J, Johnston A et al: Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. *J Invest Dermatol* **130**(7):1829-1840, 2010
247. Suarez-Farinas M et al: Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA). *PLoS One* **5**(4):e10247, 2010
248. Oestreicher JL et al: Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. *Pharmacogenomics J* **1**(4):272-287, 2001
249. Bowcock AM et al: Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. *Hum Mol Genet* **10**(17):1793-1805, 2001
250. Nomura I et al: Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. *J Immunol* **171**(6):3262-3269, 2003
251. Haider AS et al: Cellular genomic maps help dissect pathology in human skin disease. *J Invest Dermatol* **128**(3):606-615, 2008
252. Capon F et al: Searching for psoriasis susceptibility genes in Italy: Genome scan and evidence for a new locus on chromosome 1. *J Invest Dermatol* **112**(1):32-35, 1999
253. Kursar M et al: Regulatory CD4+CD25+ T cells restrict memory CD8 +T cell responses. *J Exp Med* **196**(12):1585-1592, 2002
254. Ribeiro RM et al: In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: Why are CD4+ but not CD8+ T cells depleted? *Proc Natl Acad Sci U S A* **99**(24):15572-15577, 2002
255. Gudjonsson JE et al: Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. *Br J Dermatol* **148**(2):233-235, 2003
256. Gudjonsson JE et al: HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. *J Invest Dermatol* **118**(2):362-365, 2002
257. Besgen P et al: Ezrin, maspin, peroxiredoxin 2, and heat shock protein 27: Potential targets of a streptococcal-induced autoimmune response in psoriasis. *J Immunol* **184**(9):5392-5402
258. Leung DY et al: Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. *J Clin Invest* **96**(5):2106-2112, 1995
259. Vekony MA et al: Selective amplification of T-cell receptor variable region species is demonstrable but not essential in early lesions of psoriasis vulgaris: Analysis by anchored polymerase chain reaction and hypervariable region size spectratyping. *J Invest Dermatol* **109**(1):5-13, 1997
260. Baker BS et al: Peptidoglycan and peptidoglycan-specific Th1 cells in psoriatic skin lesions. *J Pathol* **209**(2):174-181, 2006
261. Nickoloff BJ et al: Accessory cell function of keratinocytes for superantigens. Dependence on lymphocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. *J Immunol* **150**(6):2148-2159, 1993
262. Heath WR et al: Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. *Immunol Rev* **199**:9-26, 2004
263. Bennett SR et al: Help for cytotoxic-T-cell responses is mediated by CD40 signalling. *Nature* **393**(6684):478-480, 1998
264. den Haan JM, Bevan MJ: Antigen presentation to CD8+ T cells: Cross-priming in infectious diseases. *Curr Opin Immunol* **13**(4):437-441, 2001
265. Serbina NV et al: CD4(+) T cells are required for the development of cytotoxic CD8(+) T cells during Mycobacterium tuberculosis infection. *J Immunol* **167**(12):6991-7000, 2001
266. Hamilton SE et al: The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells. *Nat Immunol* **7**(5):475-481, 2006
267. Nickoloff BJ, Wrone-Smith T: Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. *Am J Pathol* **155**(1):145-158, 1999
268. Krueger GG et al: A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. *N Engl J Med* **356**(6):580-592, 2007
269. Lee E et al: Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. *J Exp Med* **199**(1):125-130, 2004
270. Bettelli E, Oukka M, Kuchroo VK: T(H)-17 cells in the circle of immunity and autoimmunity. *Nat Immunol* **8**(4):345-350, 2007
271. Najarian DJ, Gottlieb AB: Connections between psoriasis and Crohn's disease. *J Am Acad Dermatol* **48**(6):805-821, quiz 822-804, 2003
272. Duerr RH et al: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science* **314**(5804):1461-1463, 2006
273. Thomas GP, Brown MA: Genetics and genomics of ankylosing spondylitis. *Immunol Rev* **233**(1):162-180, 2010

274. Reveille JD et al: Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. *Nat Genet* **42**(2):123-127, 2010
275. Liu Y et al: A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. *PLoS Genet* **4**(3):e1000041, 2008
276. Huffmeier U et al: Genetic variants of the IL-23R pathway: Association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. *J Invest Dermatol* **129**(2):355-358, 2009
277. Mills KH: Induction, function and regulation of IL-17-producing T cells. *Eur J Immunol* **38**(10):2636-2649, 2008
278. Griffiths CE, Barker JN: Pathogenesis and clinical features of psoriasis. *Lancet* **370**(9583):263-271, 2007
279. Ghoreschi K et al: Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. *Nat Med* **9**(1):40-46, 2003
280. Guenova E et al: IL-4 therapy of psoriasis selectively abrogates IL-23 and Th17 immune responses in humans [abstract]. *J Invest Dermatol* **129**(Suppl. 2):S2, 2009
281. Mauro C et al: ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-kappaB. *J Biol Chem* **281**(27):18482-18488, 2006
282. Plenge RM et al: Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. *Nat Genet* **39**(12):1477-1482, 2007
283. Thomson W et al: Rheumatoid arthritis association at 6q23. *Nat Genet* **39**(12):1431-1433, 2007
284. Graham RR et al: Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. *Nat Genet* **40**:1059-1061, 2008
285. Musone SL et al: Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. *Nat Genet* **40**:1062-1064, 2008
286. Gateva V et al: A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. *Nat Genet* **41**(11):1228-1233, 2009
287. Han JW et al: Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. *Nat Genet* **41**(11):1234-1237, 2009
288. Idel S, Dansky HM, Breslow JL: A20, a regulator of NFkappaB, maps to an atherosclerosis locus and differs between parental sensitive C57BL/6J and resistant FVB/N strains. *Proc Natl Acad Sci U S A* **100**(24):14235-14240, 2003
289. Gelfand JM et al: Risk of myocardial infarction in patients with psoriasis. *JAMA* **296**(14):1735-1741, 2006
290. Lu T et al: Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. *Proc Natl Acad Sci U S A* **107**(1):46-51, 2010
291. Jin J et al: Systematic analysis and nomenclature of mammalian F-box proteins. *Genes Dev* **18**(21):2573-2580, 2004
292. Hunter CA: Act1-ivating IL-17 inflammation. *Nat Immunol* **8**(3):232-234, 2007
293. Jackson B et al: Late cornified envelope family in differentiating epithelia—response to calcium and ultraviolet irradiation. *J Invest Dermatol* **124**(5):1062-1070, 2005
294. Zhao XP, Elder JT: Positional cloning of skin-specific genes from the human epidermal differentiation complex. *Genomics* **45**:250-258, 1997
295. Gudjonsson JE et al: Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. *J Invest Dermatol* **130**(7):1829-1840, 2010
296. Christophers E: Psoriasis—epidemiology and clinical spectrum. *Clin Exp Dermatol* **26**(4):314-320, 2001
297. Fry L: *An Atlas of Psoriasis*. Carnforth, Parthenon Publishing, 1992
298. Weiss G, Shemer A, Trau H: The Koebner phenomenon: review of the literature. *J Eur Acad Dermatol Venereol* **16**(3):241-248, 2002
299. van de Kerkhof PC: The Woronoff zone surrounding the psoriatic plaque. *Br J Dermatol* **139**(1):167-168, 1998
300. Telfer NR et al: The role of streptococcal infection in the initiation of guttate psoriasis. *Arch Dermatol* **128**(1):39-42, 1992
301. Chalmers RR et al: A systematic review of treatments for guttate psoriasis. *Br J Dermatol* **145**(6):891-894, 2001
302. Mitchell JC, Forstner J: Eccrine function in psoriasis inversus. *J Canadian Med Assoc* **87**(21):1093-1095, 1962
303. Johnson C, Shuster S: Eccrine sweating in psoriasis. *Br J Dermatol* **81**(2):119-124, 1969
304. Cornbleet T: Action of synthetic antimalarial drugs on psoriasis. *J Invest Dermatol* **26**(6):435-436, 1956
305. Ivker RA et al: Infantile generalized pustular psoriasis associated with lytic lesions of the bone. *Pediatr Dermatol* **10**(3):277-282, 1993

306. Prose NS et al: Pustular psoriasis with chronic recurrent multifocal osteomyelitis and spontaneous fractures. *J Am Acad Dermatol* **31**(2 Pt 2):376-379, 1994
307. Beretta-Piccoli BC et al: Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome in childhood: a report of ten cases and review of the literature. *Eur J Pediatr* **159**(8):594-601, 2000
308. Baker H, Ryan TJ: Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. *Br J Dermatol* **80**(12):771-793, 1968
309. Zelickson BD, Muller SA: Generalized pustular psoriasis: A review of 63 cases. *Arch Dermatol* **127**(9):1339-1345, 1991
310. Kopp T et al: Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type. *Br J Dermatol* **151**(4):912-916, 2004
311. Newland MR, Weinstein A, Kerdel F: Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. *Int J Dermatol* **41**(7):449-452, 2002
312. Varma R et al: Infliximab for the treatment of severe pustular psoriasis: 6 years later. *J Eur Acad Dermatol Venereol* **22**(10):1253-1254, 2008
313. Umezawa Y et al: Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. *Arch Dermatol Res* **295**(Suppl. 1):S43-S54, 2003
314. Onoufriadis A et al. Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis. *Am J Hum Genet.* 2011;doi:10.1016/j.ajhg.2011.07.022
315. Marrakchi S et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. *N Engl J Med* **365**(7):620-628, 2011
316. Abou-Samra T et al: Generalized pustular psoriasis complicated by acute respiratory distress syndrome. *Br J Dermatol* **150**(2):353-356, 2004
317. Breier-Maly J et al: Generalized pustular psoriasis of pregnancy (impetigo herpetiformis). *Dermatology* **198**(1):61-64, 1999
318. Oumeish OY, Parish JL: Impetigo herpetiformis. *Clin Dermatol* **24**(2):101-104, 2006
319. Bajaj AK et al: Impetigo herpetiformis. *Dermatologica* **155**(5):292-295, 1977
320. Kroumpouzou G, Cohen LM: Dermatoses of pregnancy. *J Am Acad Dermatol* **45**(1):1-19, quiz 19-22, 2001
321. Faergemann J: Treatment of sebopsoriasis with itraconazole. *Mykosen* **28**(12):612-618, 1985
322. Happle R: Linear psoriasis and ILVEN: Is lumping or splitting appropriate? *Dermatology* **212**(2):101-102, 2006
323. Del Rosso JQ et al: Dermatologic diseases of the nail unit. In: *Nails: Therapy, Diagnosis, Surgery*, edited by RK Scher, CR Daniel. Philadelphia, W.B. Saunders, 1997, pp. 172-182
324. Kouskoukis CE, Scher RK, Ackerman AB: The "oil drop" sign of psoriatic nails. A clinical finding specific for psoriasis. *Am J Dermatopathol* **5**(3):259-262, 1983
325. Kvedar JC, Baden HP: Nail changes in cutaneous disease. *Semin Dermatol* **10**(1):65-70, 1991
326. Daneshpazhooh M et al: Tongue lesions in psoriasis: A controlled study. *BMC Dermatol* **4**(1):16, 2004
327. Lerner MR, Lerner AB: Psoriasis and protein intake. *Arch Dermatol* **90**:217-225, 1964
328. Mallbris L et al: Psoriasis is associated with lipid abnormalities at the onset of skin disease. *J Am Acad Dermatol* **54**(4):614-621, 2006
329. Wittenberg GP, Oursler JR, Peters MS: Secondary amyloidosis complicating psoriasis. *J Am Acad Dermatol* **32**(3):465-468, 1995
330. Mallbris L et al: Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. *Eur J Epidemiol* **19**(3):225-230, 2004
331. Henseler T, Christophers E: Disease concomitance in psoriasis. *J Am Acad Dermatol* **32**(6):982-986, 1995
332. Cohen AD, Weitzman D, Dreier J: Psoriasis and hypertension: A case-control study. *Acta Derm Venereol* **90**(1):23-26, 2010
333. Gelfand JM et al: The risk of lymphoma in patients with psoriasis. *J Invest Dermatol* **126**(10):2194-2201, 2006
334. Fortune DG et al: Psychologic factors in psoriasis: Consequences, mechanisms, and interventions. *Dermatol Clin* **23**(4):681-694, 2005
335. Ginsburg IH, Link BG: Feelings of stigmatization in patients with psoriasis. *J Am Acad Dermatol* **20**(1):53-63, 1989
336. Gupta MA, Gupta AK, Watteel GN: Early onset (<40 years age) psoriasis is comorbid with greater psychopathology than late onset psoriasis: A study of 137 patients. *Acta Derm Venereol* **76**(6):464-466, 1996

337. Cooper-Patrick L, Crum RM, Ford DE: Identifying suicidal ideation in general medical patients. *JAMA* **272**(22):1757-1762, 1994
338. Finlay AY et al: Validation of sickness impact profile and psoriasis disability index in psoriasis. *Br J Dermatol* **123**(6):751-756, 1990
339. Rapp SR et al: Psoriasis causes as much disability as other major medical diseases. *J Am Acad Dermatol* **41**(3 Pt 1):401-407, 1999
340. Krueger G et al: The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. *Arch Dermatol* **137**(3):280-284, 2001
341. Herron MD et al: Impact of obesity and smoking on psoriasis presentation and management. *Arch Dermatol* **141**(12):1527-1534, 2005
342. Fortes C et al: Relationship between smoking and the clinical severity of psoriasis. *Arch Dermatol* **141**(12):1580-1584, 2005
343. Kramer U, Esser C: Cigarette smoking, metabolic gene polymorphism, and psoriasis. *J Invest Dermatol* **126**(3):693-694, author reply 695, 2006
344. Whyte J, Baughman R, Hanover N: Acute guttate psoriasis and streptococcal infection. *Arch Dermatol* **89**:350-356, 1964
345. Mallon E et al: HLA-Cw*0602 and HIV-associated psoriasis. *Br J Dermatol* **139**(3):527-533, 1998
346. Duvic M et al: Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome. *Arch Dermatol* **123**(12):1622-1632, 1987
347. Kaplan MH et al: Antipsoriatic effects of zidovudine in human immunodeficiency virus-associated psoriasis. *J Am Acad Dermatol* **20**(1):76-82, 1989
348. Obuch ML et al: Psoriasis and human immunodeficiency virus infection. *J Am Acad Dermatol* **27**(5 Pt 1):667-673, 1992
349. Colebunders R et al: Psoriasis regression in terminal AIDS. *Lancet* **339**(8801):1110, 1992
350. Vittorio Luigi De Socio G, Simonetti S, Stagni G: Clinical improvement of psoriasis in an AIDS patient effectively treated with combination antiretroviral therapy. *Scand J Infect Dis* **38**(1):74-75, 2006
351. Cohen AD et al: Psoriasis associated with hepatitis C but not with hepatitis B. *Dermatology* **220**(3):218-222, 2010
352. O'Brien M, Koo J: The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. *J Drugs Dermatol* **5**(5):426-432, 2006
353. Ko JM, Gottlieb AB, Kerbleski JF: Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases. *J Dermatolog Treat* **16**:1-8, 2008
354. van de Kerkhof PC: Therapeutic strategies: Rotational therapy and combinations. *Clin Exp Dermatol* **26**(4):356-361, 2001
355. Lebwohl M, Ali S: Treatment of psoriasis. Part 1. Topical therapy and phototherapy. *J Am Acad Dermatol* **45**(4):487-498, quiz 499-502, 2001
356. van de Kerkhof PC, Vissers WH: The topical treatment of psoriasis. *Skin Pharmacol Appl Skin Physiol* **16**(2):69-83, 2003
357. Richards HL et al: Patients with psoriasis and their compliance with medication. *J Am Acad Dermatol* **41**(4):581-583, 1999
358. Griffiths CE et al: A systematic review of treatments for severe psoriasis. *Health Technol Assess* **4**(40):1-125, 2000
359. Menter A et al: Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. *J Am Acad Dermatol* **60**(4):643-659, 2009
360. Linden KG, Weinstein GD: Psoriasis: Current perspectives with an emphasis on treatment. *Am J Med* **107**(6):595-605, 1999
361. du Vivier A, Phillips H, Hehir M: Applications of glucocorticosteroids. The effects of twice-daily vs once-every-other-day applications on mouse epidermal cell DNA synthesis. *Arch Dermatol* **118**(5):305-308, 1982
362. Lehmann B: The vitamin D3 pathway in human skin and its role for regulation of biological processes. *Photochem Photobiol* **81**(6):1246-1251, 2005
363. Barna M et al: Effect of calcitriol on the production of T-cell-derived cytokines in psoriasis. *Br J Dermatol* **136**(4):536-541, 1997
364. Ramsay CA: Management of psoriasis with calcipotriol used as monotherapy. *J Am Acad Dermatol* **37**(3 Pt 2):S53-S54, 1997
365. Mortensen L et al: Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism. A randomized, double-blind, placebo-controlled study. *Acta Derm Venereol* **73**(4):300-304, 1993
366. Arbiser JL et al: Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar. *J Invest Dermatol* **126**(6):1396-1402, 2006

367. Hecker D et al: Interactions between tazarotene and ultraviolet light. *J Am Acad Dermatol* **41**(6):927-930, 1999
368. Zonneveld IM et al: Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. *Arch Dermatol* **134**(9):1101-1102, 1998
369. Gribetz C, Ling M, Lebwohl M et al: Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study. *J Am Acad Dermatol* **51**(5):731-738, 2004
370. Martin Ezquerro G et al: Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. *J Drugs Dermatol* **5**(4):334-336, 2006
371. Lebwohl M: The role of salicylic acid in the treatment of psoriasis. *Int J Dermatol* **38**(1):16-24, 1999
372. Honigsmann H: Phototherapy for psoriasis. *Clin Exp Dermatol* **26**(4):343-350, 2001
373. Ozawa M et al: 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. *J Exp Med* **189**(4):711-718, 1999
374. Walters IB et al: Narrowband (312-nm) UV-B suppresses interferon gamma and interleukin (IL) 12 and increases IL-4 transcripts: Differential regulation of cytokines at the single-cell level. *Arch Dermatol* **139**(2):155-161, 2003
375. van Weelden H et al: A new development in UVB phototherapy of psoriasis. *Br J Dermatol* **119**(1):11-19, 1988
376. Green C et al: 311 nm UVB phototherapy—An effective treatment for psoriasis. *Br J Dermatol* **119**(6):691-696, 1988
377. Van Weelden H et al: Comparison of narrow-band UV-B phototherapy and PUVA photochemotherapy in the treatment of psoriasis. *Acta Derm Venereol* **70**(3):212-215, 1990
378. Tanew A et al: Narrowband UV-B phototherapy vs photochemotherapy in the treatment of chronic plaque-type psoriasis: A paired comparison study. *Arch Dermatol* **135**(5):519-524, 1999
379. Yones SS et al: Randomized double-blind trial of the treatment of chronic plaque psoriasis: Efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. *Arch Dermatol* **142**(7):836-842, 2006
380. Iest J, Boer J: Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. *Br J Dermatol* **120**(5):665-670, 1989
381. Green C et al: A comparison of the efficacy and relapse rates of narrowband UVB (TL-01) monotherapy vs. etretinate (re-TL-01) vs. etretinate-PUVA (re-PUVA) in the treatment of psoriasis patients. *Br J Dermatol* **127**(1):5-9, 1992
382. Passeron T, Ortonne JP: Use of the 308-nm excimer laser for psoriasis and vitiligo. *Clin Dermatol* **24**(1):33-42, 2006
383. Speight EL, Farr PM: Erythematous and therapeutic response of psoriasis to PUVA using high-dose UVA. *Br J Dermatol* **131**(5):667-672, 1994
384. Asawanonda P et al: 308-nm excimer laser for the treatment of psoriasis: A dose-response study. *Arch Dermatol* **136**(5):619-624, 2000
385. Menter A et al: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. *J Am Acad Dermatol* **62**(1):114-135, 2010
386. Radakovic-Fijan S et al: Topical aminolaevulinic acid-based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer-blinded study. *Br J Dermatol* **152**(2):279-283, 2005
387. Halevy S, Sukenik S: Different modalities of spa therapy for skin diseases at the Dead Sea area. *Arch Dermatol* **134**(11):1416-1420, 1998
388. Lebwohl M, Ali S: Treatment of psoriasis. Part 2. Systemic therapies. *J Am Acad Dermatol* **45**(5):649-661, quiz 662-644, 2001
389. Strober BE, Siu K, Menon K: Conventional systemic agents for psoriasis. A systematic review. *J Rheumatol* **33**(7):1442-1446, 2006
390. Pathirana D et al: European S3-guidelines on the systemic treatment of psoriasis vulgaris. *J Eur Acad Dermatol Venereol* **23**(Suppl. 2):1-70, 2009
391. Jeffes EW III et al: Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. *J Invest Dermatol* **104**(2):183-188, 1995
392. Cronstein BN, Naime D, Ostad E: The anti-inflammatory effects of methotrexate are mediated by adenosine. *Adv Exp Med Biol* **370**:411-416, 1994
393. Strober BE, Menon K: Folate supplementation during methotrexate therapy for patients with psoriasis. *J Am Acad Dermatol* **53**(4):652-659, 2005
394. Johnston A et al: The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. *Clin Immunol* **114**(2):154-163, 2005

395. Kalb RE et al: Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. *J Am Acad Dermatol* **60**(5):824-837, 2009
396. Menon K et al: Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. *J Am Acad Dermatol* **62**(2):291-299
397. Roenigk HH Jr et al: Methotrexate in psoriasis: Revised guidelines. *J Am Acad Dermatol* **19**(1 Pt 1):145-156, 1988
398. Menter A et al: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. *J Am Acad Dermatol* **61**(3):451-485, 2009
399. Orion E, Matz H, Wolf R: The life-threatening complications of dermatologic therapies. *Clin Dermatol* **23**(2):182-192, 2005
400. Kazlow DW et al: Cutaneous ulceration caused by methotrexate. *J Am Acad Dermatol* **49**(2 Suppl. Case Reports):S197-S198, 2003
401. Lee CS, Koo J: A review of acitretin, a systemic retinoid for the treatment of psoriasis. *Expert Opin Pharmacother* **6**(10):1725-1734, 2005
402. Pilkington T, Brogden RN: Acitretin. A review of its pharmacology and therapeutic use. *Drugs* **43**(4):597-627, 1992
403. Zachariae H et al: Morphologic renal changes during cyclosporine treatment of psoriasis. Studies on pretreatment and posttreatment kidney biopsy specimens. *J Am Acad Dermatol* **26**(3 Pt 2):415-419, 1992
404. Nakayama J, Koga T, Furue M: Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis. *Eur J Dermatol* **8**(8):563-568, 1998
405. Paul CF et al: Risk of malignancies in psoriasis patients treated with cyclosporine: A 5 y cohort study. *J Invest Dermatol* **120**(2):211-216, 2003
406. Mrowietz U, Christophers E, Altmeyer P: Treatment of severe psoriasis with fumaric acid esters: Scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. *Br J Dermatol* **141**(3):424-429, 1999
407. Gupta AK et al: Sulfasalazine improves psoriasis. A double-blind analysis [see comments]. *Arch Dermatol* **126**(4):487-493, 1990
408. Hollander JL et al: The effect of triamcinolone on psoriatic arthritis—a two year study. *Arthritis Rheum* **2**:513-525, 1959
409. Zhou Y et al: Mycophenolate mofetil (CellCept) for psoriasis: a two-center, prospective, open-label clinical trial. *J Cutan Med Surg* **7**(3):193-197, 2003
410. Mason C, Krueger GG: Thioguanine for refractory psoriasis: a 4-year experience. *J Am Acad Dermatol* **44**(1):67-72, 2001
411. Kao NL, Rosenblate HJ: 6-Thioguanine therapy for psoriasis causing toxic hepatic venoocclusive disease. *J Am Acad Dermatol* **28**(6):1017-1018, 1993
412. Kirby B et al: Dermatomyositis-like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis. *Clin Exp Dermatol* **25**(3):256-257, 2000
413. Weinblatt ME et al: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med* **340**(4):253-259, 1999
414. Gottlieb AB, Bos JD: Recombinantly engineered human proteins: Transforming the treatment of psoriasis. *Clin Immunol* **105**(2):105-116, 2002
415. van de Kerkhof PC: Consistent control of psoriasis by continuous long-term therapy: The promise of biological treatments. *J Eur Acad Dermatol Venereol* **20**(6):639-650, 2006
416. Kazlow Stern D et al: The use of systemic immune moderators in dermatology: An update. *Dermatol Clin* **23**(2):259-300, 2005
417. Sterry W et al: Biological therapies in the systemic management of psoriasis: International Consensus Conference. *Br J Dermatol* **151**(Suppl. 69):3-17, 2004
418. Ellis CN, Krueger GG: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. *N Engl J Med* **345**(4):248-255, 2001
419. Werther WA et al: Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. *J Immunol* **157**(11):4986-4995, 1996
420. Krueger J et al: Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. *J Invest Dermatol* **115**(2):333, 2000
421. Leonardi CL: Efalizumab: An overview. *J Am Acad Dermatol* **49**(2 Suppl.):S98-S104, 2003
422. Major EO: Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. *Annu Rev Med* **61**:35-47, 2010

423. Feldmann M, Maini RN: Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. *Nat Med* **9**(10):1245-1250, 2003
424. Rigby WF: Distinct mechanisms of action of tumor necrosis factor antagonists: What are the clinical implications? *Semin Arthritis Rheum* **34**(5 Suppl. 1):1-2, 2005
425. Scallon B et al: Binding and functional comparisons of two types of tumor necrosis factor antagonists. *J Pharmacol Exp Ther* **301**(2):418-426, 2002
426. Chien AL, Elder JT, Ellis CN: Ustekinumab: A new option in psoriasis therapy. *Drugs* **69**(9):1141-1152, 2009
427. Kreymborg K et al: IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. *J Immunol* **179**(12):8098-8104, 2007
428. Griffiths CE et al: Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. *N Engl J Med* **362**(2):118-128, 2010
429. Cather JC, Cather JC, Abramovits W: Investigational therapies for psoriasis. *J Am Acad Dermatol* **49**(2 Suppl.):S133-S138, 2003
430. Russell CB et al: Blockade of the IL17R with AMG 827 leads to rapid reversal of gene expression and histopathologic abnormalities in human psoriatic skin [abstract]. *J Invest Dermatol* **130**:S46, 2010
431. Chan CS et al: Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. *J Am Acad Dermatol* **60**(6):962-971, 2009
432. Kalb RE et al: Treatment of intertriginous psoriasis: From the Medical Board of the National Psoriasis Foundation. *J Am Acad Dermatol* **60**(1):120-124, 2009
433. Frankel AJ et al: Treatment of psoriasis in patients with hepatitis C: From the Medical Board of the National Psoriasis Foundation. *J Am Acad Dermatol* **61**(6):1044-1055, 2009
434. Rosenbach M et al: Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation. *J Am Acad Dermatol* **62**(4):655-662, 2010
435. Kastelan M et al: Perforin expression is upregulated in the epidermis of psoriatic lesions. *Br J Dermatol* **151**(4):831-836, 2004
436. Iordanov MS et al: Cell death-induced activation of epidermal growth factor receptor in keratinocytes: Implications for restricting epidermal damage in dermatitis. *J Invest Dermatol* **125**(1):134-142, 2005
437. Wolff K et al: Phototesting and dosimetry for photochemotherapy. *Br J Dermatol* **96**(1):1-10, 1977
438. Gerber W et al: Ultraviolet B 308-nm excimer laser treatment of psoriasis: A new phototherapeutic approach. *Br J Dermatol* **149**(6):1250-1258, 2003
439. Feldman SR et al: Efficacy of the 308-nm excimer laser for treatment of psoriasis: Results of a multicenter study. *J Am Acad Dermatol* **46**(6):900-906, 2002
440. Campione E et al: Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients. *Acta Derm Venereol* **89**(3):288-291, 2009
441. Foley PA et al: Combining etanercept with traditional agents in the treatment of psoriasis: A review of the clinical evidence. *J Eur Acad Dermatol Venereol* **24**(1):1135-1143, 2010
442. Menter A et al: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. *J Am Acad Dermatol* **58**(5):826-850, 2008
443. Leonardi CL et al: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). *Lancet* **371**(9625):1665-1674, 2008
444. Leonardi CL et al: Etanercept as monotherapy in patients with psoriasis. *N Engl J Med* **349**(21):2014-2022, 2003
445. Menter A et al: Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. *J Am Acad Dermatol* **58**(1):106-115, 2008